MoonLake Immunotherapeutics AG and Helix Acquisition Corp. Announce Business Combination Agreement for Tri-specific Nanobody Sonelokimab

Merck to Acquire Harpoon Therapeutics for $680M

January 8, 2024

Biotechnology

Merck has agreed to acquire clinical-stage immunotherapy company Harpoon Therapeutics for $23.00 per share in cash, representing an approximate total equity value of $680 million. The acquisition gives Merck access to Harpoon's TriTAC / ProTriTAC platforms and lead candidate HPN328 (a DLL3-targeting T‑cell engager) to enhance its oncology pipeline; the deal is expected to close in the first half of 2024, subject to customary conditions.

Lomond Therapeutics Completes Reverse Merger with Venetian-1 and Raises $44M

November 4, 2024

Biotechnology

Lomond Therapeutics completed a reverse merger with Venetian-1 Acquisition Corp., which changed its name to Lomond Therapeutics Holdings, Inc., and closed a $44 million private placement led by existing and new investors. The financing included participation from OrbiMed, Torrey Pines Investment, Deerfield Management, American Financial Group and Heights Capital and will fund advancement of Lomond’s clinical-stage oncology programs (lomonitinib, lonitoclax and a menin inhibitor).

Curia Acquires LakePharma to Expand Biologics R&D and Manufacturing Capabilities

February 14, 2022

Biotechnology

Curia (formerly AMRI) has acquired LakePharma Inc., a US-based biologics contract research, development and manufacturing organization with operations in California, Massachusetts and Texas. The deal adds LakePharma's six facilities and ~235 employees to Curia's global network, creating expanded end-to-end capabilities from discovery through GMP manufacturing for biologics.

TriSalus Life Sciences to Become Publicly Traded via Merger with MedTech Acquisition Corporation

November 14, 2022

Healthcare Services

TriSalus Life Sciences entered into a definitive merger agreement with MedTech Acquisition Corporation (MTAC), a Nasdaq-listed special purpose acquisition company, to take TriSalus public. The combined company expects to be listed on the Nasdaq under the ticker “TLSI,” with the transaction projected to close in Q1 2023 subject to regulatory approvals and customary closing conditions.

Novartis AG Acquires Chinook Therapeutics

June 12, 2023

Biotechnology

Novartis AG agreed to acquire Chinook Therapeutics for $40 per share in cash, with contingent value rights of up to $4 per share tied to regulatory milestones —bringing total consideration to as much as approximately $3.5 billion. The acquisition, approved by both companies' boards, brings Chinook's kidney-disease pipeline into Novartis' renal portfolio and was expected to close in the second half of 2023 subject to customary conditions.

NLS Pharmaceutics to Merge with Kadimastem to Form NewcelX

June 27, 2025

Biotechnology

NLS Pharmaceutics (NASDAQ: NLSP) and Kadimastem (TASE: KDST) are progressing with their proposed merger, which would combine their CNS biopharmaceutical and off-the-shelf allogeneic cell therapy pipelines into a Nasdaq-traded company named NewcelX. The transaction is supported by financing actions (including equity financings and a $25 million committed equity facility) and shareholder approvals, with the companies targeting completion in early Q3 2025.